301246.SZ
Hubei Hongyuan Pharmaceutical Technology Co., Ltd.
SZSE · C 制造业 · CN
CNY 20.84
−1.28%Year over year
Reported trailing growth
- Revenue
- +24.3%
- EBITDA
- —
- EBIT
- +787.7%
- EPS
- +776.2%
- Free cash flow
- —
- Operating cash flow
- -44.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -2.0%
- EBITDA
- -14.3%
- EBIT
- -30.9%
- Net income
- -35.1%
- EPS
- -37.6%
- Free cash flow
- -93.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026